IDH2 mutations are beneficial in all non-M3 or cytogenetically normal AML, but IDH1 mutations decrease overall mortality and event-free survival, especially in patients with normal cytogenetics [43,44]. The gene discussed is IDH1; the disease is acute myeloid leukemia.